Influence of Cranial Radiotherapy on Outcome in Children With Acute Lymphoblastic Leukemia Treated With Contemporary Therapy

Standard

Influence of Cranial Radiotherapy on Outcome in Children With Acute Lymphoblastic Leukemia Treated With Contemporary Therapy. / Vora, Ajay; Andreano, Anita; Pui, Ching-Hon; Hunger, Stephen P; Schrappe, Martin; Moericke, Anja; Biondi, Andrea; Escherich, Gabriele; Silverman, Lewis B; Goulden, Nicholas; Taskinen, Mervi; Pieters, Rob; Horibe, Keizo; Devidas, Meenakshi; Locatelli, Franco; Valsecchi, Maria Grazia.

in: J CLIN ONCOL, Jahrgang 34, Nr. 9, 20.03.2016, S. 919-26.

Publikationen: SCORING: Beitrag in Fachzeitschrift/ZeitungSCORING: ZeitschriftenaufsatzForschungBegutachtung

Harvard

Vora, A, Andreano, A, Pui, C-H, Hunger, SP, Schrappe, M, Moericke, A, Biondi, A, Escherich, G, Silverman, LB, Goulden, N, Taskinen, M, Pieters, R, Horibe, K, Devidas, M, Locatelli, F & Valsecchi, MG 2016, 'Influence of Cranial Radiotherapy on Outcome in Children With Acute Lymphoblastic Leukemia Treated With Contemporary Therapy', J CLIN ONCOL, Jg. 34, Nr. 9, S. 919-26. https://doi.org/10.1200/JCO.2015.64.2850

APA

Vora, A., Andreano, A., Pui, C-H., Hunger, S. P., Schrappe, M., Moericke, A., Biondi, A., Escherich, G., Silverman, L. B., Goulden, N., Taskinen, M., Pieters, R., Horibe, K., Devidas, M., Locatelli, F., & Valsecchi, M. G. (2016). Influence of Cranial Radiotherapy on Outcome in Children With Acute Lymphoblastic Leukemia Treated With Contemporary Therapy. J CLIN ONCOL, 34(9), 919-26. https://doi.org/10.1200/JCO.2015.64.2850

Vancouver

Bibtex

@article{9fd4f27ddb494cfb8edfc6b322490f38,
title = "Influence of Cranial Radiotherapy on Outcome in Children With Acute Lymphoblastic Leukemia Treated With Contemporary Therapy",
abstract = "PURPOSE: We sought to determine whether cranial radiotherapy (CRT) is necessary to prevent relapse in any subgroup of children with acute lymphoblastic leukemia (ALL).PATIENTS AND METHODS: We obtained aggregate data on relapse and survival outcomes for 16,623 patients age 1 to 18 years old with newly diagnosed ALL treated between 1996 and 2007 by 10 cooperative study groups from around the world. The proportion of patients eligible for prophylactic CRT varied from 0% to 33% by trial and was not related to the proportion eligible for allogeneic stem-cell transplantation in first complete remission. Using a random effects model, with CRT as a dichotomous covariate, we performed a single-arm meta-analysis to compare event-free survival and cumulative incidence of isolated or any CNS relapse and isolated bone marrow relapse in high-risk subgroups of patients who either did or did not receive CRT.RESULTS: Although there was significant heterogeneity in all outcome end points according to trial, CRT was associated with a reduced risk of relapse only in the small subgroup of patients with overt CNS disease at diagnosis, who had a significantly lower risk of isolated CNS relapse (4% with CRT v 17% without CRT; P = .02) and a trend toward lower risk of any CNS relapse (7% with CRT v 17% without CRT; P = .09). However, this group had a relatively high rate of events regardless of whether or not they received CRT (32% [95% CI, 26% to 39%] v 34% [95% CI, 19% to 54%]; P = .8).CONCLUSION: CRT does not have an impact on the risk of relapse in children with ALL treated on contemporary protocols.",
author = "Ajay Vora and Anita Andreano and Ching-Hon Pui and Hunger, {Stephen P} and Martin Schrappe and Anja Moericke and Andrea Biondi and Gabriele Escherich and Silverman, {Lewis B} and Nicholas Goulden and Mervi Taskinen and Rob Pieters and Keizo Horibe and Meenakshi Devidas and Franco Locatelli and Valsecchi, {Maria Grazia}",
note = "{\textcopyright} 2016 by American Society of Clinical Oncology.",
year = "2016",
month = mar,
day = "20",
doi = "10.1200/JCO.2015.64.2850",
language = "English",
volume = "34",
pages = "919--26",
journal = "J CLIN ONCOL",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "9",

}

RIS

TY - JOUR

T1 - Influence of Cranial Radiotherapy on Outcome in Children With Acute Lymphoblastic Leukemia Treated With Contemporary Therapy

AU - Vora, Ajay

AU - Andreano, Anita

AU - Pui, Ching-Hon

AU - Hunger, Stephen P

AU - Schrappe, Martin

AU - Moericke, Anja

AU - Biondi, Andrea

AU - Escherich, Gabriele

AU - Silverman, Lewis B

AU - Goulden, Nicholas

AU - Taskinen, Mervi

AU - Pieters, Rob

AU - Horibe, Keizo

AU - Devidas, Meenakshi

AU - Locatelli, Franco

AU - Valsecchi, Maria Grazia

N1 - © 2016 by American Society of Clinical Oncology.

PY - 2016/3/20

Y1 - 2016/3/20

N2 - PURPOSE: We sought to determine whether cranial radiotherapy (CRT) is necessary to prevent relapse in any subgroup of children with acute lymphoblastic leukemia (ALL).PATIENTS AND METHODS: We obtained aggregate data on relapse and survival outcomes for 16,623 patients age 1 to 18 years old with newly diagnosed ALL treated between 1996 and 2007 by 10 cooperative study groups from around the world. The proportion of patients eligible for prophylactic CRT varied from 0% to 33% by trial and was not related to the proportion eligible for allogeneic stem-cell transplantation in first complete remission. Using a random effects model, with CRT as a dichotomous covariate, we performed a single-arm meta-analysis to compare event-free survival and cumulative incidence of isolated or any CNS relapse and isolated bone marrow relapse in high-risk subgroups of patients who either did or did not receive CRT.RESULTS: Although there was significant heterogeneity in all outcome end points according to trial, CRT was associated with a reduced risk of relapse only in the small subgroup of patients with overt CNS disease at diagnosis, who had a significantly lower risk of isolated CNS relapse (4% with CRT v 17% without CRT; P = .02) and a trend toward lower risk of any CNS relapse (7% with CRT v 17% without CRT; P = .09). However, this group had a relatively high rate of events regardless of whether or not they received CRT (32% [95% CI, 26% to 39%] v 34% [95% CI, 19% to 54%]; P = .8).CONCLUSION: CRT does not have an impact on the risk of relapse in children with ALL treated on contemporary protocols.

AB - PURPOSE: We sought to determine whether cranial radiotherapy (CRT) is necessary to prevent relapse in any subgroup of children with acute lymphoblastic leukemia (ALL).PATIENTS AND METHODS: We obtained aggregate data on relapse and survival outcomes for 16,623 patients age 1 to 18 years old with newly diagnosed ALL treated between 1996 and 2007 by 10 cooperative study groups from around the world. The proportion of patients eligible for prophylactic CRT varied from 0% to 33% by trial and was not related to the proportion eligible for allogeneic stem-cell transplantation in first complete remission. Using a random effects model, with CRT as a dichotomous covariate, we performed a single-arm meta-analysis to compare event-free survival and cumulative incidence of isolated or any CNS relapse and isolated bone marrow relapse in high-risk subgroups of patients who either did or did not receive CRT.RESULTS: Although there was significant heterogeneity in all outcome end points according to trial, CRT was associated with a reduced risk of relapse only in the small subgroup of patients with overt CNS disease at diagnosis, who had a significantly lower risk of isolated CNS relapse (4% with CRT v 17% without CRT; P = .02) and a trend toward lower risk of any CNS relapse (7% with CRT v 17% without CRT; P = .09). However, this group had a relatively high rate of events regardless of whether or not they received CRT (32% [95% CI, 26% to 39%] v 34% [95% CI, 19% to 54%]; P = .8).CONCLUSION: CRT does not have an impact on the risk of relapse in children with ALL treated on contemporary protocols.

U2 - 10.1200/JCO.2015.64.2850

DO - 10.1200/JCO.2015.64.2850

M3 - SCORING: Journal article

C2 - 26755523

VL - 34

SP - 919

EP - 926

JO - J CLIN ONCOL

JF - J CLIN ONCOL

SN - 0732-183X

IS - 9

ER -